Navigation Links
Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies
Date:4/21/2009

- Preclinical Studies Highlight the Ability of PS-Targeting Antibodies to Reverse the Immune Suppressing Effects of Tumors by Changing the Tumor Microenvironment and Mobilizing Key Components of the Immune System -

- Studies Confirm Peregrine's PS-Targeting Antibodies Stimulate Dendritic Cell Maturation, Inflammatory Cytokine and Chemokine Release and Recruitment of Macrophages to Tumors -

DENVER and TUSTIN, Calif., April 21 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today reported that two preclinical studies presented during the AACR 100th Annual Meeting 2009 provided further confirmation of the immunomodulatory mechanisms contributing to the anti-tumor activity of its phosphatidylserine (PS)-targeting antibodies. One study confirms the anti-tumor effects and immune stimulating ability of a fully human anti-PS antibody and the other demonstrates the ability of a second fully human anti-PS antibody to stimulate development of a critical component of the adaptive immune system.

These human PS-targeting antibodies, which are currently being evaluated for both anti-cancer and anti-viral applications, increase the number of product candidates in Peregrine's anti-PS pipeline. Peregrine's lead anti-PS antibody bavituximab is currently in Phase II clinical trials in advanced breast and lung cancers.

"These preclinical studies further elucidate the unique immunomodulatory mechanisms contributing to the observed anti-tumor activity of anti-PS antibodies in preclinical and clinical studies," said Dr. Philip Thorpe, professor of pharmacology at UT Southwestern Medical Center in Dallas, a scientific advisor to Peregrine and co-author of one
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
2. Alimera Sciences Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
3. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
4. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
5. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
6. Studies Show Combination Laser Therapy Effective At Clearing Acne, Reducing Oil Production
7. Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
8. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
9. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
10. Oridion Announces Significant Medical Studies Presented at STA
11. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... and LYON, France , Dec. 19, ... LLY ) and Adocia (Euronext Paris: FR0011184241 – ADOC) ... an ultra-rapid insulin, known as BioChaperone Lispro, for treatment ... BioChaperone Lispro relies on Adocia,s proprietary BioChaperone® technology and ... and Adocia will develop BioChaperone Lispro with the goal ...
(Date:12/17/2014)... SAN DIEGO , Dec. 17, 2014 ... and Volcano Corporation (NASDAQ: VOLC ), a global ... today announced that they have entered into a definitive merger ... offer to acquire all of the issued and outstanding shares ... equity purchase price of USD 1 billion (approx. EUR 800 ...
(Date:12/17/2014)... December 17, 2014 Revenue and earnings ... on research and development In the past 2013/14 ... by two percent to EUR 4.287 billion (last year: EUR ... 14 percent to EUR 360 million. "Overall, 2013/14 was a ... Michael Kaschke , President and CEO of Carl Zeiss AG. ...
Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8ZEISS Asserts its Position in Difficult Environment 2
... , WARSAW, Ind. , March 11 Zimmer ... in musculoskeletal care, will celebrate the 25th anniversary of the ...  The Natural Knee system offers a complete range of ...  Published clinical results show survivorship of the Natural Knee ...
... , March 11 Watson Pharmaceuticals, Inc. ... Food and Drug Administration (FDA) approval of TRELSTAR® 22.5 ... formulation of TRELSTAR®, a proven, simple and effective palliative ... launch, TRELSTAR® 22.5 mg is the first and only ...
Cached Medicine Technology:Zimmer Natural Knee Celebrates 25 Years of Excellence 2Zimmer Natural Knee Celebrates 25 Years of Excellence 3Zimmer Natural Knee Celebrates 25 Years of Excellence 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 2FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 3FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 5FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 6FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 7FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 8
(Date:12/20/2014)... 2014 (HealthDay News) -- The holidays can be anything ... with fresh trees, scented candles and other allergy triggers. ... decorations that have been packed away in dank basements ... and asthma patients," Dr. Rachna Shah, an affiliate faculty ... said in Loyola news release. Shah, who is ...
(Date:12/20/2014)... New York, New York (PRWEB) December 20, 2014 ... ) continue to move forward in U.S. ... a new study which suggests that children treated ... prolactin, a hormone linked to breast development and ... Psychopharmacology, looked at 34 children and adolescents who ...
(Date:12/20/2014)... 2014 Developers of FCPX ... new plugin for Final Cut Pro X entitled TranSlice ... 5 allows users to create hand drawn text animations ... Austin, CEO of Pixel Film Studios. “TranSlice Volume 5 ... maintaining an easy to use interface.” , TranSlice Volume ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 Today, Balfleet.com, ... announces a Christmas Sale, offering 50%-70% off on its ... holiday season. , The mother of the bride dresses ... The company is 24/7 accessible and takes pride in ... delivery. , “We are offering great discounts on our ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Sub Zero Ice ... sponsor a blood drive Sunday the 28th from 2pm-6pm at ... & Sawyer Road in Sarasota, FL. , Inquiries regarding time ... you for participating in the donating process, Sub Zero Ice ... flash frozen, custom ice cream. , About Sub Zero Ice ...
Breaking Medicine News(10 mins):Health News:Holiday Trimmings Can Trigger Allergies 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2
... ... solutions provider MainStreet Monitoring Devices selects SensorLogic’s asset tracking Cloud Computing Platform as ... the care and protection of children and seniors, including individuals challenged with autism, ... ...
... Christine ... Who,s Who for demonstrating dedication, leadership and excellence in healthcare consulting. , ... (Vocus) March 3, 2010 -- ... by Cambridge Who,s Who for demonstrating dedication, leadership and excellence in healthcare ...
... ... for stretch marks approved by the U.S. Food and Drug Administration (FDA). , ... Phoenix, AZ (Vocus) March 2, 2010 -- ... is a fractional laser treatment for stretch marks ; the only one of its ...
... ... ... ... ...
... ... ... , ... ...
... who take some types of bone-building drugs used to prevent and ... to a study by U.S. researchers published today in the ... used bisphosphonate drugs, such as Fosamax, Boniva and Zomita, for more ... as compared to those who did not, according to lead author ...
Cached Medicine News:Health News:MainStreet MD Launches Personal Safety Solutions for Children and Seniors Built On SensorLogic's Cloud Computing Platform 2Health News:MainStreet MD Launches Personal Safety Solutions for Children and Seniors Built On SensorLogic's Cloud Computing Platform 3Health News:MainStreet MD Launches Personal Safety Solutions for Children and Seniors Built On SensorLogic's Cloud Computing Platform 4Health News:Christine P. Carrington, President of NurseTesting Creative Solutions, Inducted into Cambridge Who's Who 2Health News:Christine P. Carrington, President of NurseTesting Creative Solutions, Inducted into Cambridge Who's Who 3Health News:BioCosmetic Center Utilizes FDA Approved Fractional Laser Treatment for Stretch Marks 2Health News:Step Up to Speak Up Events Use Spoken Word and African-American Greek Tradition of 'Stepping' to Raise Awareness for Organ and Tissue Donation 2Health News:Step Up to Speak Up Events Use Spoken Word and African-American Greek Tradition of 'Stepping' to Raise Awareness for Organ and Tissue Donation 3Health News:Step Up to Speak Up Events Use Spoken Word and African-American Greek Tradition of 'Stepping' to Raise Awareness for Organ and Tissue Donation 4Health News:Step Up to Speak Up Events Use Spoken Word and African-American Greek Tradition of 'Stepping' to Raise Awareness for Organ and Tissue Donation 5Health News:Step Up to Speak Up Events Use Spoken Word and African-American Greek Tradition of 'Stepping' to Raise Awareness for Organ and Tissue Donation 6Health News:Step Up to Speak Up Events Use Spoken Word and African-American Greek Tradition of 'Stepping' to Raise Awareness for Organ and Tissue Donation 7Health News:Step Up to Speak Up Events Use Spoken Word and African-American Greek Tradition of 'Stepping' to Raise Awareness for Organ and Tissue Donation 8Health News:Step Up to Speak Up Events Use Spoken Word and African-American Greek Tradition of 'Stepping' to Raise Awareness for Organ and Tissue Donation 9Health News:Step Up to Speak Up Events Use Spoken Word and African-American Greek Tradition of 'Stepping' to Raise Awareness for Organ and Tissue Donation 10Health News:Step Up to Speak Up Events Use Spoken Word and African-American Greek Tradition of 'Stepping' to Raise Awareness for Organ and Tissue Donation 11Health News:Step Up to Speak Up Events Use Spoken Word and African-American Greek Tradition of 'Stepping' to Raise Awareness for Organ and Tissue Donation 12Health News:Step Up to Speak Up Events Use Spoken Word and African-American Greek Tradition of 'Stepping' to Raise Awareness for Organ and Tissue Donation 13Health News:Major Labor Board Ruling Begins to Clear the Way for Union Elections at 51 California Healthcare Facilities 2Health News:Major Labor Board Ruling Begins to Clear the Way for Union Elections at 51 California Healthcare Facilities 3Health News:Major Labor Board Ruling Begins to Clear the Way for Union Elections at 51 California Healthcare Facilities 4Health News:Major Labor Board Ruling Begins to Clear the Way for Union Elections at 51 California Healthcare Facilities 5Health News:Major Labor Board Ruling Begins to Clear the Way for Union Elections at 51 California Healthcare Facilities 6Health News:Major Labor Board Ruling Begins to Clear the Way for Union Elections at 51 California Healthcare Facilities 7Health News:Major Labor Board Ruling Begins to Clear the Way for Union Elections at 51 California Healthcare Facilities 8Health News:Major Labor Board Ruling Begins to Clear the Way for Union Elections at 51 California Healthcare Facilities 9Health News:Major Labor Board Ruling Begins to Clear the Way for Union Elections at 51 California Healthcare Facilities 10Health News:Major Labor Board Ruling Begins to Clear the Way for Union Elections at 51 California Healthcare Facilities 11Health News:Major Labor Board Ruling Begins to Clear the Way for Union Elections at 51 California Healthcare Facilities 12Health News:Common osteoporosis drugs are associated with a decrease in risk of breast cancer 2
7 mm strong curved blade. Round handle....
3 mm diameter roller blade in line with handle. Curved shaft. Flat handle. 15 mm from curve to tip....
5 mm diameter blade. Angled 45 degrees. Hexagonal handle....
0.5 mm wide x 1.5 mm long. Angled 20 degrees. Octagonal handle....
Medicine Products: